ライフサイエンスコーパス: recurrent ovarian cancer

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ation has a limited role in the detection of recurrent ovarian cancer.

2 CT may have similar accuracy in detection of recurrent ovarian cancer.

3 l as prognostic biomarkers for patients with recurrent ovarian cancer.

4 le tolerance in the second-line treatment of recurrent ovarian cancer.

5 tin-refractory cancer cells in patients with recurrent ovarian cancer.

6 iologic activity and safety of etanercept in recurrent ovarian cancer.

7 survival in patients with platinum-sensitive recurrent ovarian cancer.

8 a novel treatment for chemotherapy-resistant/recurrent ovarian cancer.

9 y, and therapeutic efficacy of etanercept in recurrent ovarian cancer.

10 CT-2103 is active in patients with recurrent ovarian cancer.

11 sequent response to platinum chemotherapy in recurrent ovarian cancer.

12 atment for patients with platinum-sensitive, recurrent ovarian cancer.

13 t prolongation of survival for patients with recurrent ovarian cancer.

14 V ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer.

15 erapy and laparotomy-confirmed persistent or recurrent ovarian cancer.

16 weekly as a 1-hour infusion in patients with recurrent ovarian cancer.

17 vide women with a new therapeutic option for recurrent ovarian cancer.

18 modality in the treatment of metastatic and recurrent ovarian cancer.

19 ibitor that has shown antitumour activity in recurrent ovarian cancer.

20 n (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, pl

21 ted activity in patients with progressive or recurrent ovarian cancer after first-line platinum-based

22 Patients with recurrent ovarian cancer after one or two prior chemothe

23 Patients with Taxol and platinum-refractory recurrent ovarian cancer and normal CEA levels were elig

24 any agents are approved for the treatment of recurrent ovarian cancer, and the treatment of each pati

25 gents have antitumour activity in women with recurrent ovarian cancer, and their combination was acti

26 of this regimen in women with refractory or recurrent ovarian cancer are necessary before it can be

27 Topotecan is known to be active in recurrent ovarian cancer, but most prior studies have fo

28 In this era of advanced medical technology, recurrent ovarian cancer continues to be a therapeutic d

29 regimens were administered to 176 women with recurrent ovarian cancer during this time period, with a

30 erapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repai

31 Recurrent ovarian cancer is also an important setting in

32 linical value of single-agent trastuzumab in recurrent ovarian cancer is limited by the low frequency

33 y for suspected new ovarian cancer (n = 26), recurrent ovarian cancer (n = 5), or endometrial cancer

34 s activity and tolerability in patients with recurrent ovarian cancer (OC) or primary peritoneal carc

35 rous malignant ascites from highly resistant recurrent ovarian cancer patients were isolated and ampl

36 l activity in a cohort of heavily pretreated recurrent ovarian cancer patients.

37 ctive therapy against chemotherapy-resistant/recurrent ovarian cancer remains a high priority.

38 Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progres

39 One patient with recurrent ovarian cancer who received 16 courses of ther

40 Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutat

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。